



Thrive Precision Health

Quality of Life Matters, its time to Thrive."

Innovative Healthcare for Diabetics

Oct 20, 2023

Thrive Precision Health Disclaimer

Disclaimer

This Presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this Presentation, regarding the Company's future financial and stock (equities issued and held by shareholders) performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans, and objectives of management are forward-looking statements. When used in this Presentation, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events. They are based on currently available information about the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this Presentation. Nothing in this release is intended to be an offer of sale or purchase of any securities nor a solicitation of any offer for the sale or purchase of any securities by the Company, its subsidiaries, officer and directors.

Company Introduction

Overview

"We're building a global diabetes care powerhouse. We're acquiring established clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide, with a seamless digital experience. And we're aiming for a healthy profit margin, which means a strong and sustainable business for everyone involved."

How are we doing this?

"We're taking healthcare to the next level with groundbreaking technology. Imagine if your healthcare was as unique as you are. We're using AI and quantum biosensors to analyze data down to the molecular level, tailoring treatments and recommendations specifically for you. This means no more one-size-fits-all solutions. Your health decisions will be based on your personal data, ensuring you receive the most effective and personalized care possible."

What are we doing?

- 1. Advanced Technology Adoption:** By incorporating AI and quantum biosensors into our clinics, we are at the forefront of healthcare innovation. This will attract patients looking for cutting-edge solutions, driving adoption.
- 2. Personalized Care:** Our transition from a population health approach to highly individualized precision healthcare means better outcomes and patient satisfaction. Patients are more likely to choose and stick with clinics that offer personalized care.
- 3. Digital Patient Experience:** Today's patients expect a seamless digital experience. Our focus on delivering this enhances patient engagement and loyalty, which in turn drives adoption and repeat business.
- 4. Higher Margins:** Traditional clinics often struggle with inefficiencies and overhead costs. Our tech-driven approach can lead to streamlined operations and reduced costs, ultimately boosting margins.
- 5. Earnings Growth:** With increased adoption, higher margins, and satisfied patients, our clinics are poised for strong earnings growth. The 35% EBITDA target is a clear indicator of our profitability potential.
- 6. Valuation:** Investors are increasingly interested in healthcare companies that leverage technology for better patient outcomes and financial returns. Your innovative approach can lead to a higher valuation compared to traditional clinics.

In summary, our strategies not only improve patient care but also make our clinics more efficient and profitable. This combination of technology adoption, personalized care, and a digital patient experience can drive both adoption and valuation well beyond what traditional clinics can achieve in today's competitive healthcare landscape.

Company History – We can change entire markets with breakthrough technology

2021 FOUNDED IN 2021 TO BRING NOVEL VIRAL TESTING SYSTEM (QLMI SALIVA TEST) TO MARKET.

2022 FEEDBACK FROM FDA, QLMI IS "COULD BECOME THE NEW "GOLD STANDARD" TO REPLACE PCR, BUT REQUIRES ADDITIONAL TESTING"

2023 PIVOT TO FIND COMMERCIAL READY TECHNOLOGIES WHILE FDA APPROVAL PROCESS CONTINUES.

2023 TAKE COMPANY PUBLIC IN MARCH 2023 TO PROVIDE ACCESS TO CAPITAL MARKETS.

2023 DEVELOPED A NOVEL INSULIN THERAPY (PIR), ACQUIRING 2 CLINICS IN ARIZONA AND 2 IN HAWAII.

2024+ OPEN 20 CLINICS IN HAWAII AND 30 MORE CLINICS IN ARIZONA – BUILD THE DIGITAL CLINIC AND PATIENT FOOTPRINT.

Comprehensive Strategy – Where Tech meets Health Care in the Public Market

1

Public Company through an RTO with OTC:CNER
(completed)

2

PIR
Developed
(complete)

Acquire 2
clinics in
Hawaii
(progressing)

Acquire – 2
clinics in
Arizona
(progressing)

Focus:

1. Revenue and Cash Flow
2. Innovative Diabetes treatments
3. Improve technology to support rapid global scaling
4. Build an excellent management team
5. Build a liquid capital market to use shares as a currency for funding and acquisitions

3

Scale Globally (2024): Introduce Precision Health using Web3 technology and miniLab for the Home
(core relationships in place)

Comprehensive Strategy – Business Drivers




Per Clinical Total
revenue potential




Planned footprint in
Hawaii (build)



Planned footprint in
Arizona (buy then
build)





To cash flow
positive from start
up of each clinic



Total Annual
Revenues with 52
clinics

Adoption of the three core technologies (PIR, Digital Platform and quantum biosensor) can increase all these metrics positively adding new efficiencies and new revenue streams

Investor Returns of a Public HealthTech Companies



Potential Valuation Drivers of the Strategy


1. Acquire or build Diabetes Clinics, typical valuation 1.2x revenue
2. Double for a public company multiple – liquidity premium
3. Using the TNQ platform implement the digital patient (add scale and reduce costs)
4. Using TNQ platform implement the digital clinician (add scale and reduce costs)
5. Using the quantum biosensor adds precision health to the service offering

Each of the valuation contributors could be cumulative, the multiple could be 20x to 53x of revenue

Disclaimer: The multiples of revenue shown in this example are for demonstration only and Thrive is not representing that these will be or may Thrive's multiples of revenue.

Investor Returns driven by Web 3 Technology

Revenue and Valuation



Assumptions (Potential Effect)

- 1. Adding clinics year over year adds revenue and earnings
- 2. Adding in technologies year over year drives revenue acceleration, patient retention, and earnings acceleration
- 3. Moving to a precision health model currently unseen in Healthcare will command the highest multiple

Demonstrates Exponential valuation growth with the adoption of AI and quantum biosensors over 5 years

Why Diabetes? We can improve outcomes

Over 10% of the world's population are Diabetic costing nearly \$1 Trillion USD annually!

KEY STATISTICS

- In the US, over 100M people have diabetes at a cost of over \$325B annually.
- In Hawaii, 133,000 people have Diabetes and 400,000 people are pre-Diabetic (roughly 40% of the entire state population).
- In Arizona, 800,000 have Diabetes and 1.6M are pre-Diabetic.
- New treatments and technologies are now emerging to help protect this vulnerable patient group.
- These treatments are covered by Medicare and the commercial insurance companies.



Market Opportunity -Hawaii is a \$100M/year revenue opportunity – Arizona \$400M/Year

TOTAL ADDRESSABLE MARKET

- **TAM Hawaii:** 133,000 active diabetics
 - 400,000 pre-diabetics: ~2.5% annual conversion (13,300)
- **TAM Arizona:** 800,000 active diabetics
 - 1,623,457 pre-diabetics: ~2.5% annual conversion (40,586)
- **Medicare reimbursement:**
 - \$5,560 reimbursement for 12 week PIR service
- **TAM (initial treatment only):**
 - **Hawaii:** \$740M in revenue (PIR Only)
 - **Arizona:** \$4.4 Billion in revenue (PIR Only)



Immediate Opportunity – Hawaii

Thrive Precision Health to open clinics in Hawaii

DIABETIC HEALTH USING PIR (and Services)

- Partnered with Insight Vascular (start up team) serving 4,000 diabetic patients – together we deliver PIR to these 4,000 patients in Hawaii
- Acquire 2 clinics in late 2023 in Hawaii
- Five more clinics in 2024 (7 Total Clinics) and have a total of 20 in 2025
- Expansion to targeted locations throughout 2025
- Clinic Revenue: ~\$5,000,000 per clinic per year with 35% EBITDA




Immediate Opportunity – Arizona

Thrive Precision Health to Acquire 2 Clinics in Arizona

DIABETIC HEALTH USING PIR

- Acquisition of True Health Clinics, 2 Clinics are currently operational
- Revenue potential for 2 clinics by end of FY24 \$10.44M with 30% EBITDA
- Full diabetes and wound care focus
- Scale up PIR as the lead, innovative offering increasing EBITDA by 5%
- Full operational team and leadership team to assist in design of the global clinical design for the Digital Patient and the Digital Clinician.
- All stock deal, plus provision of operating capital to scale up operations to profitability.




Immediate Opportunity

What is PIR (Physiologic Insulin Resensitization)

Physiologic Insulin Resensitization (PIR) is a groundbreaking multi-patented approach where insulin is administered as a hormone rather than a drug, addressing the primary cause of diabetes, metabolic failure.

This procedure is covered by Medical Insurance in the USA

More data is being collected to expand coverage and made available to more insurers



* Adapted from Pubility of Insulin Release - A Clinically Important Phenomenon, (Upstate Journal of Medical Science, 2000;114:199-2000).

Immediate Opportunity

How it Works: PIR (Physiologic Insulin Resensitization)

How Diabetic IV Therapy Works

We utilize a revolutionary, multi-patented Physiologic Insulin Resensitization (PIR) system that provides individualized patient care where **insulin is administered as a hormone rather than a drug**. By using insulin in a manner that bio-mimics normal glucose metabolism, we can help you regulate your body once again!

The treatment is designed to reduce insulin resistance, which is the primary cause of type 2 diabetes and other metabolic disorders.

Increases the Conversion of Sugar Into Energy

Treatment has been shown to:



(Schull Institute Study Insulin Infusion Therapy on Diabetic Complications (Oct 27, 2015))

Long-term Growth Opportunity

THRIVE PRECISION HEALTH

- 20+ clinics in Hawaii by 2026
- 32+ clinics in Arizona by 2026
- Expand into Hospital partnerships in Hawaii in 2024
- West Coast US expansion in 2024/2025
- Discussions underway with Qatar group for MENA Region
- Discussions underway with Thai group for ASEAN countries
- Discussions underway with Canadian group for Canada
- Discussions underway with German group for EU



Key Strategic Relationships

Precision care puts the science behind each patient


Technology and Service Providers

Bringing leading edge technology together to deliver an all-digital service to the Patient, the Clinics and its stakeholders




Clinical Platform

Develop a consistent brand and clinical delivery platform to scale out across the world.



Key Strategic Relationships


Insight Vascular Consultants (Key Advisory Services)



Focus: Start up Thrive Precision Health (Hawaii Flag Ship Clinic) using PIR Therapy as the lead service offering

Strategic Relationship

1. Provide critical start up team in Hawaii (Medical Director, Nurse Practitioner, Nursing Assistant and Clinic Operations Staff)
2. Currently over 4,500 Diabetic Patients – PIR referral program
3. Attached Clinic space for 20 IV chairs
4. Credentials team
5. Clinical service delivery and Best Practices
6. Future acquisition due diligence and Practice Integration



Key Strategic Relationships

TrueNorth Quantum Inc. – decentralizing healthcare at scale – Web3

TrueNorthQUANTUM

FACT SHEET

Powering the Decentralized Economy

Enabling industry innovators to build and launch scalable, secure decentralized applications 5x faster.

Blockchain Barriers to Entry are Holding Back Innovation

In a quickly evolving market, speed to market is key, but many developers are forced to implement a lightweight MVP that isn't built to navigate the complex technological challenges of building in the decentralized economy.

TECHNICAL INTEROPERABILITY

SECURITY

SCALE LIMITATIONS

INFRASTRUCTURE COMPLEXITY

REGULATORY UNCERTAINTY

Strategic Relationship

1. Platform as a Service provider with the Thrive Precision Application developed and operated exclusively for Thrive
2. Decentralized platform allowing patients, providers, suppliers, investors, operators and researchers to all connect securely and in real time
3. Highly secure with all regulatory requirements for privacy and security being met
4. 24-7 CyberDefense system built in from day one, AI monitoring and countermeasures deployment
5. Built on the blockchain so patient data and data rights are governed by the patient
6. Easy additions of payment currency, DEFI and NFT protocols added for new service offerings

Focus: Institutionalize Diabetes Care at scale: application and platform exclusive for Thrive Precision.

Key Strategic Relationships

Qanik DX Inc. – miniLab for Home Blood Testing (Precision Health)
using the patented quantum BioSensor



Strategic Relationship

1. Equity interest in Qanik DX and expanding that interest over time
2. Exclusive territory license with opportunity to develop a unique diabetes test panel exclusive to Thrive
3. Will be available to our Clinic's first, then to our patients for constant and test anytime capability
4. Secured data cloud integrated into the clinical platform
5. Facilitates large scale adoption from population health (one size fits all) to precision health, individualized care based with molecular data.

Focus: Develop a multiplex Blood Test for clinic and home use: exclusive to Diabetes Care understanding each patient individually

Test at home with a single drop of blood: Glucose, Insulin, HbA1c, C-Peptide, Testosterone, Estradiol, Progesterone, TSH, T3 and T4, many more are in development.

Key Strategic Relationships

Qanik DX Inc. – Spectral Fluorescence Signal Detection of Organic Matter Bacteria, Virus, Human Cell Health



Lab of the Go for the surface detection of Bacteria and Viruses



Patent pending Saliva Activator used for collection of saliva and direct testing for the presence of Virions such as SARS-Covid-2..

Non-Invasive Detection within the Clinic

1. Part of the investment in Qanik DX, Thrive has access to advanced SFS Photonic technology to be used for biosafety within the clinic and patient diagnosis.
2. For clinic biosafety application scanning surfaces for infectious pathogens like bacteria and viruses will ensure patient and staff safety
3. Upon FDA approval COVID 19 and other respiratory and highly contagious airborne viruses can be detected in saliva upon entry of the clinic.
4. SFS capability can be used in wound care to instantly determine the presence of bacterial in the wound itself.
5. Detection of vascular disorders and wound cellular margins against healthy tissue identifying the precise wound boundaries.

Thrive Six Month Objectives

1 COMPLETE RTO AND PRIVATE PLACEMENT

2 ACQUIRE 2 CLINICS IN ARIZONA
ACQUIRE 2 CLINICS IN HAWAI, 5 CLINICS IN 2024

3 FUTURE RAISE OF \$10-20+M ON PUBLIC MARKETS TO FUEL
GROWTH

4 LAUNCH THE DIGITAL CLINIC PLATFORM FOR INTERNAL USE



Executive Team



MICHAEL PFEFFER

PRESIDENT & FOUNDER

Over 25 years of experience as an entrepreneur, CEO, Angel Investor and Venture Capitalist. More than half a dozen successful exits, ranging from 1x to more than 300x returns.



GUY ZAJONC, JD

CEO & FOUNDER

40 years of experience as a business lawyer and entrepreneur, counseling numerous start-ups, early-stage private and public companies.



SHARON ANDERSON MORRIS

FOUNDER

CEO of FiReFilms, supporting scientifically based documentaries from conception through distribution to educate, inspire, and transform humanity. FiReFilms is an initiative of the Strategic News Service

Science & Advisory Team



GARY BARTHOLOMEW
ADVISOR

Built 12 tech companies, 5 IPO's, created \$1.5B in market cap, public company CEO and Chairman expertise



SERGEY BABICHENKO, PHD
CHIEF R&D OFFICER

Expertise in laser and spectroscopy technologies & photonics. 2 Medical Devices Commercialized. 120 Scientific Papers & 12 Patents in photonics



JAAK JARV, SCD
CHIEF SCIENCE OFFICER

Secretary General, Estonian Academy of Sciences, Professor 270 Scientific Papers & 2 Patents in computational biochemistry



ALEKSEI KUZNETSOV, PHD
CHIEF CHEMIST

Research Associate of the Chair of Organic Chemistry, Univ. of Tartu. 28 published papers, 2 patents.

Thrive Precision Health Advisory and Operational Team



Hardeep Reddick, PA-C, MBA

Clinical Director

Experienced healthcare practitioner and executive having built and managed several multimillion-dollar healthcare companies.



Amr El-Sergany, MD, RPVI

Medical Director


Specialized in the management of vascular pathologies such as diabetes and vascular surgeries



Nancy Clark

Billing Reimbursements

20 years experience of multi-specialty coding for each procedure or visit.



Debbie Lennick

Credentialing Specialist

Credentialing with Medicare and Medicaid and other insurance companies critical for reimbursements

Thrive Precision Health Arizona Clinical Team



Jason Mulder

[Meet Jason Mulder](#)
Founder

Dr. Jason Mulder
Chief Executive Officer

Experienced healthcare practitioner and executive having built and managed several multimillion-dollar healthcare companies.



Dr. Robert Bouvier, MD
Medical Director - Board Advisor

Experienced healthcare practitioner and executive having built and managed several multimillion-dollar healthcare companies.



Patrick Smith, MBA
Chief Operations Officer

Experienced in healthcare operations, clinical scaleup, patient experience and technology.



LuAnn Penchuk, FNP
Medical Provider

Experienced healthcare practitioner with extensive hospital and clinical wound care experience.



Liezi Naude, RN
Practice Facilitator, Advanced Wound Care


Experienced healthcare practitioner and clinical facilitator in wound care excellence through clinical practice and holistic wound management training.



THRIVE PRECISION HEALTH INC.

Michael Pfeffer

President and Co-founder

 US Mobile: 808-349-3169

 Michael@thrivebiosafety.com

 www.thrivebiosafety.com